Generation Bio Co. (NASDAQ:GBIO) Given Average Recommendation of “Hold” by Brokerages

Generation Bio Co. (NASDAQ:GBIO) has been assigned an average rating of “Hold” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $8.8750.

Several equities analysts have commented on GBIO shares. Wall Street Zen raised Generation Bio to a “sell” rating in a report on Saturday, February 14th. Zacks Research raised Generation Bio to a “hold” rating in a report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a research report on Thursday, January 22nd. Wedbush set a $5.50 target price on Generation Bio and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Finally, Citigroup reaffirmed a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th.

Hedge Funds Weigh In On Generation Bio

A number of hedge funds have recently made changes to their positions in the business. Y Intercept Hong Kong Ltd bought a new stake in Generation Bio in the second quarter valued at about $47,000. DRW Securities LLC bought a new position in Generation Bio during the fourth quarter worth about $249,000. Geode Capital Management LLC boosted its holdings in Generation Bio by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 51,795 shares of the company’s stock valued at $294,000 after purchasing an additional 1,990 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in Generation Bio during the third quarter valued at approximately $136,000. Finally, Shay Capital LLC bought a new stake in shares of Generation Bio in the 3rd quarter valued at approximately $64,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Stock Performance

NASDAQ GBIO opened at $5.34 on Friday. The firm has a 50-day simple moving average of $5.49 and a 200 day simple moving average of $5.66. Generation Bio has a twelve month low of $3.00 and a twelve month high of $8.20. The stock has a market cap of $35.99 million, a PE ratio of -0.57 and a beta of 2.05.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.